Sarcoma News and Research

RSS

USC's Keck School of Medicine researcher named recipient of NCI Outstanding Investigator Award

Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.

23 Mar 2016

Researchers find new innate immunity pathway that protects mammals from viral oncogenesis

Building upon earlier research, investigators at UT Southwestern Medical Center and their collaborators have identified a new innate immunity pathway that protects mammals from viral oncogenesis, the process by which viruses cause normal cells to become cancerous.

14 Mar 2016

Experts to analyse latest advances in diagnosis, treatment of soft tissue sarcoma at PharmaMar seminar

The creation of a network of centres of reference and adopting measures that promote research and access to treatments are two key aspects for improving the prognosis of patients with soft tissue sarcoma (STS), an uncommon type of cancer that originates in the tissues that connect, support and surround other body structures, such as muscles, fat, blood vessels, nerves, tendons and lining of the joints.

11 Mar 2016

New screening technique to test drug compounds used in Ewing sarcoma treatment

In Ewing sarcoma, cancer cells' DNA is unwound abnormally from a condensed, compact state. Once sections of genetic code are open, key genes are turned on to help direct aggressive and cancerous cell growth.

1 Mar 2016

Researchers reveal how stress conditions favor lytic reactivation of herpesviruses

Hiding their DNA genome inside the nucleus of the infected cells, the herpesviruses establish a lifelong infection in humans. Not well defined stress conditions are known to wake up these parasites from their dormancy - the latent phase - and reactivate the production of new viral progeny, eventually causing cell death by lysis - the lytic phase.

25 Feb 2016

Newly developed intravital microscopy system proves safe for use in humans

A team of Roswell Park Cancer Institute researchers has developed and evaluated the first intravital microscopy system shown to be safe for use in humans. Writing in the journal Nature Communications, the scientists report that their proprietary technology enabled them, for the first time ever, to visualize tumor blood vessels in real time.

22 Feb 2016

Wistar researchers find potential way for using STAT3 inhibitors to stop cancer progression

Imagine developing a drug designed to inhibit a protein that helps cancer cells proliferate and survive only to find that the drug does not perform very well in the clinic. This was the dilemma faced by scientists researching inhibitors of signal transducer and activator of transcription (STAT3), a protein that controls transcription by the STAT3 gene.

17 Feb 2016

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

1 Feb 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

DNA imprinting defect may affect children diagnosed with osteosarcoma

Children diagnosed with osteosarcoma may be impacted by a DNA imprinting defect also found in parents, according to new research from the Masonic Cancer Center, University of Minnesota. DNA imprinting is a phenomenon in which just one of the two inherited genes is active while the other is present but inactive.

27 Jan 2016

Champions Oncology begins prospective correlative trial of PDX in patients with sarcoma

Champions Oncology today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft PDX models) in patients with metastatic or recurrent sarcoma. Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.

21 Jan 2016

New injectable agent can potentially increase surgeon's ability to remove cancerous tumor during surgery

Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon's ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology and Lumicell Inc.

7 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

St. Jude Children's Research Hospital scientists have discovered how an aggressive tumor of the muscle and soft tissue hijacks an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy.

22 Dec 2015

USF professors named 2015 Fellows of the National Academy of Inventors

University of South Florida professors Selim A. Chacour, David M. Eddy, Dean F. Martin, and G. Douglas Letson have been named 2015 Fellows of the National Academy of Inventors. Chacour and Eddy are in the Institute for Advanced Discovery & Innovation, Martin is in the College of Arts and Sciences and Letson holds appointments at both Moffitt Cancer Center and USF.

17 Dec 2015

FIRS calls for continued international support to end AIDS epidemic by 2030

World AIDS Day, held annually on the first day of December each year since 1988, is an opportunity for people around the world to join in the fight, show their support for those living with human immunodeficiency virus (HIV), and commemorate the lives of those who have died.

7 Dec 2015

Role of genetic predisposition in pediatric cancer patients

The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer.

19 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015